Q3 Earnings Forecast for Zymeworks Issued By HC Wainwright

Zymeworks Inc. (NASDAQ:ZYME) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of Zymeworks in a report released on Monday, August 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of $2.13 per share for the quarter, up from their prior estimate of $2.09. HC Wainwright currently has a “Buy” rating and a $51.00 target price on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.26 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at ($0.56) EPS and FY2027 earnings at ($1.72) EPS.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The business had revenue of $4.59 million during the quarter, compared to the consensus estimate of $4.54 million. During the same quarter in the previous year, the business earned $0.03 earnings per share. The firm’s revenue was down 90.6% compared to the same quarter last year.

Several other analysts also recently weighed in on ZYME. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Zymeworks in a research note on Monday. Truist Financial boosted their target price on Zymeworks from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, August 7th. B. Riley Financial reissued a “buy” rating and issued a $44.00 target price (up from $40.00) on shares of Zymeworks in a research note on Monday. Finally, Stifel Nicolaus set a $46.00 price target on Zymeworks in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Zymeworks presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.75.

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $24.32 on Wednesday. The company has a 50 day simple moving average of $23.99 and a two-hundred day simple moving average of $24.46. Zymeworks has a fifty-two week low of $12.50 and a fifty-two week high of $29.75. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -12.04 and a beta of 1.15.

Zymeworks announced that its board has approved a stock repurchase plan on Thursday, May 14th that allows the company to buyback $125.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 7% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Zymeworks

Several institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new position in Zymeworks in the 4th quarter valued at approximately $37,000. Quarry LP bought a new stake in shares of Zymeworks in the 3rd quarter worth $50,000. Tower Research Capital LLC TRC raised its stake in shares of Zymeworks by 29.6% in the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after purchasing an additional 1,131 shares during the last quarter. State of Wyoming purchased a new position in shares of Zymeworks in the second quarter worth $73,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Zymeworks by 25.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock valued at $96,000 after purchasing an additional 731 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Theravance acquisition supports strategic growth. Theravance Biopharma reported second-quarter results in line with expectations and is set to be acquired by Zymeworks in a deal valued at approximately $929 million. The transaction follows Theravance’s cost-cutting efforts and discontinuation of ampreloxetine, and could strengthen Zymeworks’ portfolio of licensed healthcare assets. TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
• Positive Sentiment: HC Wainwright maintained a bullish view. The firm reiterated its “Buy” rating and $51 price target, well above recent trading levels. The continued target support may reinforce investor confidence in Zymeworks’ asset and royalty strategy, despite projected losses in several 2027 quarters.
• Positive Sentiment: Upcoming conferences may improve investor visibility. Management plans to meet investors and hold fireside chats at Wells Fargo, Citi, Morgan Stanley and H.C. Wainwright conferences in September, providing opportunities to discuss Ziihera, pasritamig, the Theravance transaction and its broader biotherapeutics pipeline. Zymeworks Announces Participation in Upcoming Investor Conferences
• Neutral Sentiment: Short-interest data provides no usable signal. Reported short interest was zero on both the latest and prior reporting dates, with a zero-day days-to-cover ratio. Because the report also shows an invalid “NaN” percentage change, the figures should not be interpreted as evidence of changing bearish sentiment.
• Negative Sentiment: Analyst estimates were reduced. HC Wainwright lowered its FY2026 EPS forecast to $0.31 from $0.36, while forecasting losses of $0.45, $0.44, $0.42 and $0.42 per share for the first four quarters of 2027. Zymeworks’ recent results also showed a substantial year-over-year revenue decline and a quarterly EPS loss, highlighting execution and profitability risks.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.